Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Kamada in a report on Saturday, September 3rd. Jefferies Group reissued a “buy” rating and issued a $7.00 price objective on shares of Kamada in a research report on Wednesday, August 31st. Finally, TheStreet raised Kamada from a “sell” rating to a “hold” rating in a research report on Monday, September 26th.
Kamada (NASDAQ:KMDA) traded down 0.38% on Wednesday, reaching $5.23. The company’s stock had a trading volume of 15,575 shares. The firm’s market cap is $190.47 million. Kamada has a 12 month low of $3.26 and a 12 month high of $5.45. The firm has a 50 day moving average of $4.82 and a 200 day moving average of $4.10.
Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Kamada had a negative return on equity of 10.59% and a negative net margin of 9.92%. The business earned $19.10 million during the quarter, compared to the consensus estimate of $18.50 million. Analysts anticipate that Kamada will post ($0.19) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock valued at $652,000 after buying an additional 4,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Kamada during the second quarter worth approximately $1,701,000. 5.31% of the stock is currently owned by institutional investors and hedge funds.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.